Alexandros Makriyannis Selected Research

Messenger RNA (mRNA)

3/2024	CB 1 Cannabinoid Receptor Agonists Induce Acute Respiratory Depression in Awake Mice.
3/2012	Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems.
11/2009	Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexandros Makriyannis Research Topics

Disease

28	Pain (Aches) 01/2024 - 09/2001
18	Inflammation (Inflammations) 02/2024 - 10/2003
15	Hyperalgesia 03/2024 - 10/2003
12	Obesity 12/2020 - 10/2007
11	Neuralgia (Stump Neuralgia) 01/2022 - 09/2003
11	Hypothermia 10/2018 - 09/2001
9	Neoplasms (Cancer) 12/2022 - 12/2016
8	Substance-Related Disorders (Drug Abuse) 01/2021 - 10/2007
7	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2024 - 03/2008
7	Tobacco Use Disorder (Nicotine Dependence) 01/2019 - 01/2012
6	Catalepsy 01/2024 - 09/2001
6	Peripheral Nervous System Diseases (PNS Diseases) 01/2023 - 11/2008
6	Hypersensitivity (Allergy) 01/2021 - 09/2003
4	Neuroinflammatory Diseases 04/2024 - 01/2021
4	Fibrosis (Cirrhosis) 02/2024 - 03/2012
4	Body Weight (Weight, Body) 10/2020 - 12/2007
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 04/2006
4	Weight Loss (Weight Reduction) 12/2016 - 08/2006
4	Nausea 01/2016 - 07/2007
3	Respiratory Insufficiency (Respiratory Failure) 03/2024 - 10/2021
3	Insulin Resistance 10/2020 - 08/2010
3	Vomiting 01/2020 - 12/2007
3	Multiple Sclerosis 01/2018 - 07/2005
3	Seizures (Absence Seizure) 09/2017 - 09/2007
3	Colitis 02/2015 - 11/2009
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2015 - 01/2006
2	Retinal Diseases 10/2023 - 01/2021
2	Triple Negative Breast Neoplasms 12/2022 - 01/2022
2	Carcinogenesis 01/2022 - 02/2019
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 10/2011
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020 - 01/2019
2	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 11/2019 - 10/2018
2	Abdominal Pain (Pain, Abdominal) 11/2019 - 10/2018
2	Hyperphagia (Overeating) 01/2019 - 10/2011
2	Glaucoma 01/2019 - 07/2005
2	Marijuana Abuse (Cannabis Abuse) 01/2016 - 11/2002
2	Dementia (Dementias) 01/2014 - 11/2008
2	Weight Gain 10/2011 - 12/2007
2	Overweight 03/2009 - 03/2008
2	Immune System Diseases (Immune Disorders) 11/2008 - 03/2008

Drug/Important Bio-Agent (IBA)

42	CannabinoidsIBA 03/2024 - 09/2001
28	EndocannabinoidsIBA 04/2024 - 03/2003
17	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 02/2024 - 07/2005
12	AM 1241IBA 01/2022 - 09/2001
12	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 12/2002
11	AM4113IBA 02/2024 - 12/2007
11	CB2 Cannabinoid ReceptorIBA 01/2022 - 02/2003
10	Paclitaxel (Taxol)FDA LinkGeneric 03/2024 - 11/2008
10	RimonabantIBA 03/2019 - 02/2004
9	anandamide (arachidonylethanolamide)IBA 01/2023 - 08/2002
9	N-acylethanolaminesIBA 12/2022 - 02/2015
9	3- (1,1- dimethyl- heptyl)- 1- hydroxy- 9- methoxy- benzo(c)chromen- 6- oneIBA 01/2022 - 06/2011
8	Analgesics (Analgesic Drugs)IBA 01/2024 - 02/2003
7	AcidsIBA 12/2022 - 02/2015
6	Opioid Analgesics (Opioids)IBA 10/2022 - 02/2013
6	Morphine (MS Contin)FDA LinkGeneric 10/2022 - 02/2013
6	amidaseIBA 01/2022 - 02/2015
6	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 01/2021 - 08/2002
6	Nicotine FDA Link 01/2020 - 04/2012
5	Cannabinoid Receptor AgonistsIBA 03/2024 - 02/2003
5	Dronabinol (THC)FDA LinkGeneric 03/2024 - 12/2012
5	AM6545IBA 02/2024 - 10/2017
5	EnzymesIBA 01/2021 - 03/2012
5	Proteins (Proteins, Gene)FDA Link 12/2020 - 08/2002
5	LigandsIBA 04/2016 - 03/2008
4	Glycerol (Glycerine)FDA LinkGeneric 04/2024 - 10/2012
4	CytokinesIBA 12/2022 - 03/2012
4	palmidrolIBA 01/2021 - 02/2015
4	LipidsIBA 01/2021 - 08/2010
3	Messenger RNA (mRNA)IBA 03/2024 - 11/2009
3	Monoacylglycerol LipasesIBA 01/2022 - 03/2012
3	methanandamideIBA 10/2021 - 02/2013
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 02/2015
3	N-(4-hydroxyphenyl)arachidonylamide (AM404)IBA 01/2016 - 03/2003
3	3- (1- hexylcyclobut- 1- yl)- 6a,7,8,9,10,10a- hexahydro- 6,6- dimethyl- 6H- dibenzo(b,d)pyran- 1,9 diolIBA 08/2015 - 03/2012
3	AM 251 (AM251)IBA 04/2014 - 12/2007
3	Glycoproteins (Glycoprotein)IBA 01/2014 - 11/2008
3	9- (hydroxymethyl)- 3- (1- adamantyl)hexahydrocannabinolIBA 08/2013 - 01/2013
2	MonoglyceridesIBA 11/2023 - 01/2016
2	Fatty Acids (Saturated Fatty Acids)IBA 11/2023 - 01/2013
2	AmidesIBA 12/2022 - 01/2013
2	AlbuminsIBA 02/2021 - 10/2017
2	Interleukin-10 (Interleukin 10)IBA 12/2020 - 03/2012
2	Serotonin (5 Hydroxytryptamine)IBA 11/2019 - 10/2018
2	AM9405IBA 11/2019 - 10/2018
2	N- pyridazin- 3- yl- 4- (3- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)benzylidene)piperidine- 1- carboxamideIBA 01/2019 - 01/2019
2	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 02/2013
2	Therapeutic UsesIBA 12/2018 - 10/2011
2	Ethanol (Ethyl Alcohol)IBA 01/2018 - 11/2008
2	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2014 - 02/2013
2	iodopravadoline (AM 630)IBA 04/2014 - 11/2009
2	Sulfonic AcidsIBA 01/2014 - 11/2009
2	Mesylates (Mesylate)IBA 02/2013 - 01/2013
2	pyrazoleIBA 02/2013 - 02/2004
2	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA 01/2013 - 08/2006
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2011 - 11/2008

Therapy/Procedure

13	Therapeutics 01/2024 - 09/2003
8	Analgesia 01/2024 - 05/2005
8	Drug Therapy (Chemotherapy) 01/2022 - 03/2008
2	Ligation 01/2019 - 09/2003